Dr. William Kelly, MD
What this data tells you about Dr. Kelly
Dr. William Kelly is a medical oncology specialist in San Antonio, TX, with 12 years of NPI registration. Based on federal Medicare data, Dr. Kelly performed 17,900 Medicare services across 688 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kelly received a total of $198 from 4 pharmaceutical and/or device companies across 5 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kelly is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 8,000 | $43 | $164 |
| Anti-nausea injection (fosaprepitant) | 4,500 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 2,640 | $19 | $69 |
| Dexamethasone injection (steroid) | 796 | $0 | $0 |
| Anti-nausea injection (ondansetron/Zofran) | 656 | $0 | $0 |
| Anti-nausea injection (Aloxi/palonosetron) | 290 | $1 | $5 |
| Administration of chemotherapy into vein, 1 hour or less | 164 | $97 | $376 |
| Injection of additional new drug or substance into vein | 160 | $12 | $46 |
| Office visit, established patient (30-39 min) | 110 | $96 | $312 |
| Injection, magnesium sulfate, per 500 mg | 108 | $1 | $2 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 93 | $22 | $86 |
| Drug injection, under skin or into muscle | 43 | $11 | $41 |
| Administration of chemotherapy into vein, each additional hour | 43 | $22 | $85 |
| Administration of additional new drug or substance into vein, 1 hour or less | 43 | $50 | $192 |
| Office visit, established patient, complex (40-54 min) | 41 | $135 | $438 |
| Injection, diphenhydramine hcl, up to 50 mg | 33 | $1 | $3 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $56 | $214 |
| Infusion into a vein for hydration, each additional hour | 25 | $10 | $38 |
| Infusion, normal saline solution , 1000 cc | 25 | $2 | $8 |
| Initial hospital admission, high complexity | 24 | $136 | $436 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $49 | $192 |
| Unclassified drugs | 20 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 19 | $16 | $61 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $26 | $97 |
Industry Payment Transparency
Open Payments through 2022 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2022)
Associated products mentioned in payments ›
Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2022 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kelly is a mixed practice specialist, with moderate Medicare volume, with low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kelly experienced with pembrolizumab injection (keytruda)?
Does Dr. Kelly receive payments from pharmaceutical companies?
How do Dr. Kelly's costs compare to other medical oncologists in San Antonio?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology